调强放疗联合内分泌治疗前列腺癌的临床研究  

Clinical study on the combination of intensity-modulated radiotherapy and endocrine therapy for prostate cancer

作　　者：王玮 Wang Wei(Department of Urology,Shanxi Cancer Hospital,Shanxi Hospital Cancer Hospital Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,Shanxi,China)

机构地区：[1]山西省肿瘤医院/中国医学科学院肿瘤医院山西医院/山西医科大学附属肿瘤医院泌尿外科,山西太原030013

出　　处：《中国男科学杂志》2025年第1期76-80,共5页Chinese Journal of Andrology

摘　　要：目的观察分析调强放疗联合内分泌治疗前列腺癌的临床疗效。方法选取2020年1月—2024年1月在我院进行治疗的70例前列腺癌患者作为本次研究对象,采用平均法将其分为对照组和试验组,每组各35例。对照组采用内分泌治疗联合常规放疗,试验组采用调强放疗联合内分泌治疗。分析比较两组细胞免疫指标、肿瘤标志物水平、生存质量评分、临床疗效以及不良反应率。结果治疗后,试验组免疫指标、PSA、fPSA水平、治疗有效率、生存质量评分、不良反应率均显著优于对照组(P<0.05)。结论调强放疗联合内分泌治疗前列腺癌,能有效降低肿瘤标志物水平,提高机体免疫力,具有令人满意的疗效,且安全性较好。Objective Observation and analysis of the clinical efficacy of intensity-modulated radiotherapy combined with endocrine therapy for prostate cancer.Method 70 prostate cancer patients who received treatment in our hospital from January 2020 to January 2024 were selected as the subjects of this study.They were divided into a control group and an experimental group using the average method,with 35 patients in each group.The control group received endocrine therapy combined with conventional radiotherapy,while the experimental group received intensity-modulated radiotherapy combined with endocrine therapy.Analyze and compare two groups of cellular immune indicators,tumor marker levels,quality of life scores,clinical efficacy,and adverse reaction rates.Result After treatment,the immune indicators,PSA,fPSA levels,treatment efficacy,quality of life score,and adverse reaction rate in the experimental group were significantly better than those in the control group(P<0.05).Conclusion The combination of intensity-modulated radiotherapy and endocrine therapy for prostate cancer can effectively reduce tumor marker levels,improve the body's immunity,and has satisfactory efficacy and good safety.

关 键 词：调强放疗 内分泌治疗 前列腺肿瘤 治疗结果 

分 类 号：R737.25[医药卫生—肿瘤] R730.55[医药卫生—临床医学]